Drug Approval | March 01, 2022
USFDA approves CITI Biopharma’s Vonjo
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Biogen paid Ionis a US $ 60 million one-time upfront payment
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Subscribe To Our Newsletter & Stay Updated
